The T. Rowe Price Health Sciences strategy is among the better options available given its strong investment resources, research depth, and framework.
T. Rowe Price Health Sciences PRHSX
- NAV / 1-Day Return 94.85 / +1.28 %
- Total Assets 15.2 Bil
-
Adj. Expense Ratio
- Expense Ratio 0.800%
- Distribution Fee Level Below Average
- Share Class Type No Load
- Category Health
- Investment Style Large Growth
- Min. Initial Investment 2,500
- Status Open
- TTM Yield —
- Turnover 48%
USD | NAV as of Mar 27, 2024 | 1-Day Return as of Mar 27, 2024, 10:23 PM GMT+0
Morningstar’s Analysis PRHSX
Will PRHSX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 50.0
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Aggregate Miscellaneous Equity | 9.56 | 1.4 Bil | — |
UnitedHealth Group Inc | 8.08 | 1.2 Bil | Healthcare |
Eli Lilly and Co | 8.04 | 1.2 Bil | Healthcare |
Thermo Fisher Scientific Inc | 4.73 | 695.5 Mil | Healthcare |
Intuitive Surgical Inc | 3.82 | 562.2 Mil | Healthcare |
Elevance Health Inc | 3.54 | 520.1 Mil | Healthcare |
Merck & Co Inc | 3.51 | 516.2 Mil | Healthcare |
Stryker Corp | 3.24 | 477.1 Mil | Healthcare |
Danaher Corp | 2.77 | 407.2 Mil | Healthcare |
Vertex Pharmaceuticals Inc | 2.73 | 401.2 Mil | Healthcare |